Q1 EPS Estimate for BioLife Solutions Increased by Analyst

BioLife Solutions, Inc. (NASDAQ:BLFS) – Research analysts at Northland Capmk boosted their Q1 2025 earnings per share estimates for shares of BioLife Solutions in a research note issued on Monday, March 3rd. Northland Capmk analyst C. Byrnes now forecasts that the medical equipment provider will post earnings of ($0.02) per share for the quarter, up from their previous estimate of ($0.03). The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.03) EPS.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the previous year, the company posted ($0.21) EPS.

A number of other brokerages have also issued reports on BLFS. Northland Securities upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Craig Hallum upped their price target on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. TD Cowen upped their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright dropped their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Finally, Benchmark restated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.43.

BioLife Solutions Stock Performance

Shares of BLFS opened at $26.25 on Thursday. The business’s 50 day moving average is $26.67 and its two-hundred day moving average is $25.48. BioLife Solutions has a 52-week low of $14.84 and a 52-week high of $29.55. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -24.76 and a beta of 1.91. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC bought a new position in shares of BioLife Solutions in the 4th quarter valued at approximately $26,000. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of BioLife Solutions during the 3rd quarter worth approximately $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in BioLife Solutions in the 4th quarter valued at $31,000. Quest Partners LLC acquired a new stake in BioLife Solutions in the 3rd quarter valued at $57,000. Finally, 1620 Investment Advisors Inc. boosted its stake in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 675 shares in the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Insider Transactions at BioLife Solutions

In other news, CFO Troy Wichterman sold 987 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the transaction, the chief financial officer now owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Aby J. Mathew sold 7,604 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the transaction, the executive vice president now directly owns 276,315 shares of the company’s stock, valued at $7,551,688.95. This represents a 2.68 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,978 shares of company stock valued at $322,724. 2.20% of the stock is currently owned by corporate insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.